HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
Rivoceranib named Best of ESMO 2019
HLB announced that Rivoceranib Phase 3 clinical trial results were announced as Best of ESMO 2019 along with Opdibo® and Keytruda®.
With attracting academic interest whether Rivoceranib will be recognized as Korea's first global anticancer drug, This year's ESMO collected 3,904 different studies (about 15% more than the previous year) under the great amount of interest from the oncologists around the world.
Based on the announcement, Riboseranib has proven its effectiveness in both of the two prominent oncology societies since it was selected as the Best of ASCO 2014 with the presentation of phase 3 clinical trials of gastric cancer in China.